ERT Announces Appointment of New President and CEO

PHILADELPHIA, PA – 04 May, 2011 ERT, a global technology-driven provider of clinical services and customizable medial devices to biopharmaceutical and healthcare organizations, announced today that its Board of Directors has appointed Jeffrey S. Litwin, M.D. its new President and Chief Executive Officer and as a member of the board.

Dr. Joel Morganroth, who had served as interim President and Chief Executive Officer, commented that "after a thorough national search by Heidrick and Struggles, our Board selected Dr. Litwin, an internal candidate, as the most qualified person to lead ERT.  Jeff brings to ERT knowledge of the Clinical Research domain, that is our core business, and also experience in the adjacent markets of Phase IV safety surveillance and healthcare in which ERT's assets will be employed.  All of our employees look forward to continuing to work with Jeff to enhance ERT's operational successes and strategy."

Dr. Litwin joined ERT in 2000 as Senior Vice President and Chief Medical Officer and was subsequently promoted in December 2005 to Executive Vice President and Chief Medical Officer.  Dr. Litwin oversaw ERT's global cardiac safety operations for seven years and was instrumental in implementing EXPERT, ERT's digital operating system.  During this time period, ERT experienced tremendous growth with revenues increasing more than three-fold. For the last four years, he has been responsible for leading ERT's consulting business, assisting over 150 companies with the design and evaluation of cardiac safety testing programs.  Throughout his career at ERT, Dr. Litwin has also been directly involved in supporting ERT's sales efforts.

ERT Awarded over $10 Million of ePRO Business from Major Pharma - Increasing its Position as a Leading ePRO Provider

PHILADELPHIA, PA - 14 April 2011 ERT, a global technology-driven provider of clinical services and customizable medical devices to biopharmaceutical and healthcare organizations, announced today that it was awarded three new contracts with top tier pharmaceutical companies, totaling over $10 million for its electronic patient reported outcomes (ePRO) business. The company has been selected to provide its diverse multi-modality solutions, reinforcing its position as a leading provider of multi-mode ePRO devices and services.